Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Organ transplantation is a modern medical success story. However, since its inception it has been limited by the need for pharmacological immunosuppression. Regulatory cellular therapies offer an attractive solution to these challenges by controlling transplant alloresponses through multiple parallel suppressive mechanisms. A number of cell types have seen an accelerated development into human trials and are now on the threshold of a long-awaited breakthrough in personalized transplant therapeutics. Here we assess recent developments with a focus on the most likely candidates, some of which have already facilitated successful immunosuppression withdrawal in early clinical trials. We propose that this may constitute a promising approach in clinical transplantation but also evaluate outstanding issues in the field, providing cause for cautious optimism.

Original publication

DOI

10.1016/j.it.2021.11.001

Type

Journal article

Journal

Trends Immunol

Publication Date

01/2022

Volume

43

Pages

8 - 21

Keywords

cellular therapy, clinical trials, immunosuppression, organ transplantation, tolerance, Cell- and Tissue-Based Therapy, Humans, Immune Tolerance, Immunosuppression Therapy, Organ Transplantation, Transplantation Tolerance